Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism

J Thromb Haemost. 2018 Jun;16(6):1040-1051. doi: 10.1111/jth.14016. Epub 2018 May 8.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but feared long-term complication of acute pulmonary embolism (PE), although CTEPH may occur in patients with no history of symptomatic venous thromboembolism. It represents the most severe presentation of the so-called 'post-PE syndrome', a phenomenon of permanent functional limitations after PE caused by deconditioning after PE or ventilatory or circulatory impairment as a result of unresolved pulmonary artery thrombi. Because the post-PE syndrome may occur in up to 50% of PE survivors, and CTEPH tends to have an insidious and non-specific clinical presentation, CTEPH is often not diagnosed or diagnosed after a very long delay. Once the diagnosis is confirmed, the treatment of choice is pulmonary endarterectomy which effectively lowers the pulmonary vascular resistance and normalizes resting pulmonary artery pressures, leading to recovery of the right ventricle. When pulmonary endarterectomy is not technically feasible, balloon pulmonary angioplasty may be a potential acceptable alternative. Also, medical treatment may help to improve patient's symptoms and hemodynamics. Current studies are focusing on strategies for earlier CTEPH diagnosis after acute PE, as well as the most optimal treatment of inoperable patients. This review will focus on the epidemiology, risk factors, diagnosis and treatment of CTEPH from the perspective of the PE patient.

Keywords: diagnosis; prognosis; pulmonary embolism; pulmonary hypertension; treatment.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon
  • Anticoagulants / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Arterial Pressure* / drug effects
  • Blood Coagulation* / drug effects
  • Chronic Disease
  • Endarterectomy
  • Humans
  • Hypertension, Pulmonary* / diagnosis
  • Hypertension, Pulmonary* / epidemiology
  • Hypertension, Pulmonary* / physiopathology
  • Hypertension, Pulmonary* / therapy
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / physiopathology*
  • Pulmonary Artery / surgery
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / epidemiology
  • Pulmonary Embolism* / physiopathology
  • Pulmonary Embolism* / therapy
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Antihypertensive Agents

Associated data

  • GENBANK/NCT02555137